ClinicalTrials.gg
TerminatedNCT03278626Updated Mar 28, 2022Results posted

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

A Phase 1/2 interventional study of Nivolimumab+Carboplatin/paclitaxel+Radiation in Esophageal Squamous Cell Carcinoma, sponsored by NYU Langone Health. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by NYU Langone Health · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was stopped earlier than anticipated due to slow accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma — 2 open to participants now, 3 under way, none of them phase 3. Nivolumab · Esophageal Squamous Cell Carcinoma.

Enrollment
9th of 10
12 · median 46
Started
2017
the only one that year
Phase 1/2
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
1 of 10
NYU Langone Health

Among the 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma, this one is the 9th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 1st registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

2 of the 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care established by the CROSS trial: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks. Concurrent radiation will be administered with chemotherapy at 1.8 Gy/fraction × 28 fractions to a total dose of 50.4 Gy, the standard radiation dose administered in the United States for trimodality therapy that includes concurrent therapy with carboplatin and paclitaxel. A decrease in dose to 41.4 Gy per the protocol established by van Hagen, et al. will be permitted before discontinuing therapy due to unacceptable toxicity. While the CROSS study administered only 5 weekly doses of chemotherapy during the 5 weeks of radiation, the higher dose of 50.4 Gy (1.8 Gy/fraction ×28 fractions over 5½ weeks) utilized in this study permits for a sixth dose during the additional week of radiation.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • Locally Advanced Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed, treatment-naive esophageal squamous cell carcinoma
  • Previously obtained , or tissue obtained by endoscopically guided core biopsy at screening
  • TanyN1-3 or T3-4 N0as determined by EUS and PET/CT. All palpable or CT/PET visible lymph nodes outside the usual surgical field must be biopsy-proven negative for cancer.
  • All patients must have locoregional staging determined by endoscopic ultrasound (EUS) if technically feasible. Endoscopy reports or subsequent GI clinic note should clearly state both the T and N stage.
  • All patients must have initial PET/CT scans to document no evidence of or unresectable squamous cell cancer
  • All patients with tumors involving the thoracic esophagus must undergo bronchoscopy to document the absence of a fistula No known to the use of taxanes or platinum compounds.
  • No history of severe reaction to Cremophor® EL.
  • Patients who are ≥ 18 years old are eligible for this study. Neither specific gender distribution, nor specific racial or ethnic origins are necessary for enrollment in this study.
  • (ECOG) Performance Status 0-1
  • A patient must be capable of giving or have an acceptable surrogate capable of giving consent on the subject's behalf
  • Deemed a suitable candidate for esophagectomy by the treating surgeon as documented in a pre-operative assessment visit per standard practice at each participating institution.
  • Deemed a suitable candidate for radiation therapy by the treating radiation oncologist as documented in a standard pretreatment visit per standard practice at each participating institution.
  • Patient must be non-pregnant and non-nursing. Women of child bearing potential () must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to C1D1.
  • Screening Laboratory Values must meet the following criteria and should be obtained within 14 days prior to C1D1 (see Table 1 below)
  • Patients with a positive core antibody (HBVcAb) must have negative viral load measurement; Patients with HBV core positive, must have negative viral load measurements
  • Screening Laboratory Values must meet the following criteria and should be obtained within 14 days prior to randomization/registration (see Table 1 below) Test Acceptable Result WBC ≥ 2000/µL Neutrophils ≥ 1500/µL ≥ 100,000 /µL > 9.0 g/dL Serum Creatinine ≤ 1.5 x OR (CrCl)* ≥ 40 mL/min ≤ 3 x ULN ALT ≤ 3 x ULN Total ** ≤ 1.5 x ULN

Oxygen Saturation (O2 Sat.) ≥92% on ambient air Hepatitis B status HBV Surface Antigen Negative HBV Surface Antibody Positive or Negative HBV Core Antibody Negative status Anti-HCV Total Antibody Negative HCV RNA analysis Negative status Rapid HIV 1/2 Antibodies Negative *Creatinine Clearance Calculated using the Cockcroft-Gault formula

Female CrCl = (140- age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL

Male CrCl = (140- age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL

**Total Bilirubin ≤ 1.5 x ULN, except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL

Exclusion criteria

Exclusion Criteria:

  • T1-2 N0 as determined by EUS and PET/CT.
  • Pregnant or lactating women
  • Active or prior documented or inflammatory disorders including but not limited to inflammatory bowel disease; systemic lupus erythematosus; type I diabetes mellitus; Wegener syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
  • Subjects with vitiligo or alopecia
  • Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan
  • The use of medication within 28 days prior to the first dose of nivolumab. The following are exceptions to this criterion:
  • Intranasal, topical, inhaled or local steroid injections (e.g. intra-articular injection)
  • Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or equivalent
  • Steroids as premedication for reactions (e.g. CT scan premedication
  • Positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Active or (defined as positive-HBV surface antigen or detectable HCV-antibody) indicating acute or chronic infection. Patients with a positive Hepatitis B core antibody (HBVcAb) must have negative viral load measurement.
  • Prior treatment with any immunotherapy
  • Any other factors, including psychiatric or social, that in the opinion of the treating physician makes the patient an inappropriate candidate for a study.
  • Patients are excluded if they have active or . Subjects with brain metastases are eligible if have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for [lowest minimum is 4 weeks or more] after treatment is complete and within 28 days prior to the first dose of nivolumab administration. There must also be no ESCC Nivolumab requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
  • Patients should be excluded if they have an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • As there is potential for hepatic toxicity with nivolumab or nivolumab non-drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen.
  • Patients with a history of allergy to the study drug components are excluded.
  • No herbal supplements are allowed in this protocol.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Other
    Nivolimumab+Carboplatin/paclitaxel+Radiation

    240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation

    Drug: Nivolimumab+Carboplatin/paclitaxel+Radiation

Interventions

  • DrugNivolimumab+Carboplatin/paclitaxel+Radiation

    Drug page: Nivolumab

    In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).

    Also known as: Opdivo, Paraplatin, Taxol

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Unacceptable Toxicity (UT) Events

    UT is defined as: 1. Recurrent grade 3 or 4 hematologic toxicity (despite 1 prior dose reduction in chemotherapy) 2. any toxicity that results in a \> 2-week delay in chemoradiation

    Time frame: 92 days (up to 28 days after Day 64)

  2. Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response)

    Clinical and pathological response after neoadjuvant therapy cCR by endoscopic + PET/CT evaluation; pCR for patients undergoing surgery Clinical Complete Response (cCR), no malignancy is found on clinical examination, imaging, endoscopy, and biopsy; Pathological Complete Response (pCR), no invasive and no in situ residual tumors in tissue

    Time frame: 5-8 Weeks post radiation treatment (7-8 months after treatment start)

07

Results

Posted Mar 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneNivolimumab+Carboplatin/Paclitaxel+Radiation
Started12
Completed7
Not completed5
Withdrew: Death2
Withdrew: Toxicity1
Withdrew: Disease progression2

Outcome measures

PrimaryPhase 1: Number of Unacceptable Toxicity (UT) Events

UT is defined as: 1. Recurrent grade 3 or 4 hematologic toxicity (despite 1 prior dose reduction in chemotherapy) 2. any toxicity that results in a \> 2-week delay in chemoradiation

Time frame:
92 days (up to 28 days after Day 64)
Reported as:
Number · Unacceptable Toxicity Events
Phase 1: Number of Unacceptable Toxicity (UT) Events
Unacceptable Toxicity EventsNivolimumab+Carboplatin/Paclitaxel+Radiation
Phase 1: Number of Unacceptable Toxicity (UT) Events0
PrimaryPhase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response)

Clinical and pathological response after neoadjuvant therapy cCR by endoscopic + PET/CT evaluation; pCR for patients undergoing surgery Clinical Complete Response (cCR), no malignancy is found on clinical examination, imaging, endoscopy, and biopsy; Pathological Complete Response (pCR), no invasive and no in situ residual tumors in tissue

Time frame:
5-8 Weeks post radiation treatment (7-8 months after treatment start)
Reported as:
Count of participants · Participants
Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response)
ParticipantsNivolimumab+Carboplatin/Paclitaxel+Radiation
Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response)1

Adverse events

Collected over 100 days post-treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolimumab+Carboplatin/Paclitaxel+Radiation2/12 (16.7%)6/12 (50%)12/12 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventNivolimumab+Carboplatin/Paclitaxel+Radiation
Abdominal PainGastrointestinal disorders1/12
Lung InfectionInfections and infestations1/12
ColitisGastrointestinal disorders1/12
DeathGeneral disorders1/12
FeverGeneral disorders1/12
ConfusionPsychiatric disorders1/12
AspirationRespiratory, thoracic and mediastinal disorders1/12
Myocardial InfarctionCardiac disorders1/12
Rash-MorbiliformSkin and subcutaneous tissue disorders1/12
DysphagiaGastrointestinal disorders1/12
Most frequent other events
Showing 10 of 93
Most frequent other events
EventNivolimumab+Carboplatin/Paclitaxel+Radiation
AnemiaBlood and lymphatic system disorders11/12
Decreased Lymphocyte CountInvestigations10/12
Decreased Platelet CountInvestigations9/12
Decreased Wbc CountInvestigations9/12
DysphagiaGastrointestinal disorders8/12
Decreased Neutrophil CountInvestigations7/12
HypokalemiaMetabolism and nutrition disorders7/12
NauseaGastrointestinal disorders7/12
ConstipationGastrointestinal disorders6/12
FatigueGeneral disorders6/12

Baseline characteristics

6 subjects enrolled in Phase 1, and 6 subjects enrolled in Phase 2

Age, Continuous
Age, Continuous(years)Nivolimumab+Carboplatin/Paclitaxel+Radiation
Median63.95 (47.03 to 86.17)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolimumab+Carboplatin/Paclitaxel+Radiation
Female5
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolimumab+Carboplatin/Paclitaxel+Radiation
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolimumab+Carboplatin/Paclitaxel+Radiation
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American2
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nivolimumab+Carboplatin/Paclitaxel+Radiation
United States12
08

Study locations

5 sites
  • University of Califonia, San Diego
    La Jolla, California 92093, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Nov 2019, 28 months.

Results were first posted in Mar 2022, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2017
First posted
Sep 11, 2017
StartActual
Jun 27, 2017
Primary completionActual
Nov 7, 2019
CompletionActual
May 31, 2021
Results first posted
Mar 28, 2022
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03278626
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Jun 27, 2017
Primary completion
Nov 7, 2019
Completion
May 31, 2021
Results posted
Mar 28, 2022
Last update
Mar 28, 2022

Study contacts

Jennifer Wu, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion